Statement on Johnson & Johnson COVID-19 Vaccine

covid vaccine

The U.S. Centers for Disease Control & Prevention (CDC) and the U.S. Food & Drug Administration (FDA) have recommended a pause in the use of the Janssen (Johnson & Johnson) COVID-19 vaccine in the United States, effective Tuesday, April 13.

This decision was made out of an abundance of caution, as the CDC and FDA are reviewing data involving six (6) reported cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. All six cases occurred among women ages 18-48, with symptoms developing between 6 to 13 days after vaccination. To date, over 6.8 million doses of the Janssen/J&J vaccine have been administered in the United States. To read the joint statement by the CDC & FDA, CLICK HERE.

Acacia Network, La Casa De Salud, and Promesa Inc. have discontinued offering the J&J vaccine, pending further official guidelines. We will continue to offer the Moderna vaccine to all eligible individuals.

People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. If you received the J&J vaccine through one of our health centers and have questions regarding this notice, please contact us at: J&